A Nordic Phase II Study of PTCL Based on Dose-intensive Induction and High-dose Consolidation With ASCT
Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
This is a phase II prospective non-randomised clinical trial in newly diagnosed and
previously untreated adult patients in the age range 18-60 (67) years with peripheral T-cell
lymphoma.
The treatment schedule will consist of three phases: induction and high-dose consolidation,
followed by autologous stem cell rescue. There will be two different induction schedules: one
for patients in the age range 18-60 years and one for patients aged over 60 years.